口服中药治疗膝骨关节炎疗效与安全性的系统评价与Meta分析
该系统评价与Meta分析纳入31项随机对照试验共3115例膝骨关节炎患者,评估口服中药的疗效与安全性。结果显示中药在WOMAC、VAS、Lequesne指数、Lysholm评分及部分炎症指标上优于安慰剂或西药,中药联合西药优于单用西药。但纳入研究存在偏倚,有效成分尚需进一步研究,结论需高质量RCT确认。
要点
- 口服中药改善膝骨关节炎的WOMAC、VAS及Lequesne指数优于安慰剂或西药。
- 中药联合西药在多项疗效指标上优于单用西药。
- 纳入研究存在偏倚,结论需高质量RCT进一步确认。
核心结论
- 口服中药治疗膝骨关节炎的疗效优于安慰剂和西药。
- 中药联合西药治疗膝骨关节炎的疗效优于单用西药。
- 因纳入研究存在偏倚且中药有效成分需进一步研究,不能得出肯定结论,需高质量RCT确认。
研究设计与样本
- 系统评价与Meta分析,检索7个数据库自建库至2021年8月的随机对照试验。
- 共纳入31项随机对照试验、3115例病例。
- 采用GRADE进行质量评价,RevMan5.4进行Meta分析。
主要发现
- WOMAC:中药vs安慰剂SMD=-0.87(95%CI:-1.27至-0.47,P<0.0001);中药vs西药SMD=-1.64(95%CI:-2.09至-1.19,P<0.00001);中药+西药vs西药SMD=-2.17(95%CI:-3.01至-1.33,P<0.00001)。
- VAS:中药vs西药SMD=-1.02(95%CI:-1.63至-0.41,P<0.00001);中药+西药vs西药SMD=-2.68(95%CI:-4.36至-1.00,P<0.00001)。
- Lequesne严重指数:中药vs西药SMD=-0.90(95%CI:-1.40至-0.39,P=0.0005);中药+西药vs西药SMD=-0.94(95%CI:-1.36至-0.52,P<0.0001)。
- Lysholm膝关节功能评分:中药vs西药MD=9.10(95%CI:4.20至14.01,P=0.0003);单项试验中中药+西药vs西药MD=21.15(95%CI:19.71至22.59,P<0.00001)。
- SOD:单项试验中中药vs西药MD=1.62(95%CI:0.9至2.30,P<0.00001);中药+西药vs西药MD=17.08(95%CI:10.71至23.44,P<0.00001);TNF-α:中药vs西药SMD=-1.90(95%CI:-2.04至-0.14,P=0.02),中药+西药vs西药SMD=-2.32(95%CI:-4.33至-0.30,P=0.02);IL-1β:中药vs西药SMD=-1.60(95%CI:-2.36至-0.84,P<0.0001);IL-6:单项试验中中药vs西药MD=-0.75(95%CI:-1.20至-0.30,P=0.001),中药+西药vs西药MD=-3.18(95%CI:-6.24至-0.12,P=0.04)。
关键数值与推荐
- 纳入31项RCT,共3115例膝骨关节炎患者,比较口服中药与安慰剂、西药或中药联合西药与单用西药。
- WOMAC、VAS、Lequesne指数、Lysholm评分及SOD、TNF-α、IL-1β、IL-6等指标显示中药组或联合组优于对照组,具体数值见主要发现。
临床怎么用
- 膝骨关节炎患者可考虑口服中药单用或联合西药以改善症状和功能。
- 使用中药时需结合患者具体情况,并关注纳入研究偏倚对证据强度的影响。
局限性
- 纳入研究存在一定偏倚。
- 中药有效成分尚需进一步研究。
- 不能得出肯定结论,需高质量临床RCT确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aims to evaluate the effectiveness and safety of oral Chinese herbal medicine (CHM) in the treatment of knee osteoarthritis (KOA). STUDY DESIGN: Systematic review and meta-analysis of randomized controlled trials (RCTs). MATERIALS AND METHODS: A computer was used to retrieve all RCTs of CHM in the treatment of KOA from 7 databases (PubMed; Embase; Cochrane Central Register of Controlled Trials; China National Knowledge Infrastructure; Chinese VIP Information Database; Chinese Biomedical Database and Wanfang Med Database) from the establishment to August 2021. The literature was organized using NoteExpress, and literature screening and data extraction were conducted by two researchers independently by the inclusion and exclusion criteria. Quality evaluation was performed using GRADE, and the meta-analysis was performed using RevMan5.4. RESULTS: A total of 31 RCTs and 3115 cases are included. The following meta-analysis results are observed: (1) WOMAC: CHM vs. placebo (SMD = -0.87, 95% CI: -1.27 to -0.47, P < 0.0001), CHM vs. Western medicine (SMD = -1.64, 95% CI: -2.09 to -1.19, P < 0.00001), and CHM + Western medicine vs. Western medicine (SMD = -2.17, 95% CI: -3.01 to -1.33, P < 0.00001); (2) VAS: CHM vs. Western medicine (SMD = -1.02, 95% CI: -1.63 to -0.41, P < 0.00001) and CHM + Western medicine vs. Western medicine (SMD = -2.68, 95% CI: -4.36 to -1.00, P < 0.00001); (3) Lequesne severity index: CHM vs. Western medicine (SMD = -0.90, 95% CI: -1.40 to -0.39, P = 0.0005) and CHM + Western medicine vs. Western medicine (SMD = -0.94, 95% CI: -1.36 to -0.52, P < 0.0001); (4) Lysholm knee joint function score: CHM vs. Western medicine (MD = 9.10, 95% CI: 4.20 to 14.01, P = 0.0003), and CHM + Western medicine vs. Western medicine in a single trial (MD = 21.15, 95% CI: 19.71 to 22.59, P < 0.00001); (5) SOD: in a single trial, CHM vs. Western medicine (MD = 1.62, 95% CI: 0.9 to 2.30, P < 0.00001) and CHM + Western medicine vs. Western medicine (MD = 17.08, 95% CI: 10.71 to 23.44, P < 0.00001); (6) TNF-α: CHM vs. Western medicine (SMD = -1.90, 95% CI: -2.04 to -0.14, P = 0.02) and CHM + Western medicine vs. Western medicine (SMD = -2.32, 95% CI: -4.33 to -0.30, P = 0.02); (7) IL-1β: CHM vs. Western medicine (SMD = -1.60, 95% CI: -2.36 to -0.84, P < 0.0001); and (8) IL-6: in a single trial, CHM vs. Western medicine (MD = -0.75, 95% CI: -1.20 to -0.30, P = 0.001) and CHM + Western medicine vs. Western medicine (MD = -3.18, 95% CI: -6.24 to -0.12, P = 0.04). CONCLUSION: The efficacy of CHM in the treatment of KOA is superior to those of placebo and Western medicine. At the same time, the combination of CHM + Western medicine is superior to Western medicine alone in the treatment of KOA. However, due to the existence of certain biases in the included studies, and the need for further study on the effective components of Chinese medicine, a positive conclusion on the efficacy of traditional CHM in the treatment of KOA cannot be drawn and needs to be confirmed by high-quality clinical RCTs.
引用
- Liang Y, Xu Y, Zhu Y, et al. Efficacy and Safety of Chinese Herbal Medicine for Knee Osteoarthritis: Systematic Review and Meta-analysis of Randomized Controlled Trials. Phytomedicine. 2022. PMID: 35316726. doi:10.1016/j.phymed.2022.154029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。